Literature DB >> 8958216

Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources.

L Chen1, M Pulsipher, D Chen, C Sieff, A Elias, H A Fine, D W Kufe.   

Abstract

Tumor contamination of bone marrow (BM) and peripheral blood (PB) may affect the outcome of patients receiving high dose chemotherapy with autologous transplantation of hematopoietic stem cell products. In this report, we demonstrate that replication defective adenoviral vectors containing the cytomegalovirus (CMV) or DF3/MUC1 carcinoma-selective promoter can be used to selectively transduce contaminating carcinoma cells. Adenoviral-mediated reporter gene expression in breast cancer cells was five orders of magnitude higher than that found in BM, PB, and CD34+ cells. Our results demonstrate that CD34+ cells have low to undetectable levels of integrins responsible for adenoviral internalization. We show that adenoviral-mediated transduction of a reporter gene can detect one breast cancer cell in 5 x 10(5) BM or PB cells with a vector containing the DF3/MUC1 promoter. We also show that transduction of the HSV-tk gene for selective killing by ganciclovir can be exploited for purging cancer cells from hematopoietic stem cell populations. The selective expression of TK followed by ganciclovir treatment resulted in the elimination of 6-logs of contaminating cancer cells. By contrast, there was little effect on CFU-GM and BFU-E formulation or on long term culture initiating cells. These results indicate that adenoviral vectors with a tumor-selective promoter provide a highly efficient and effective approach for the detection and purging of carcinoma cells in hematopoietic stem cell preparations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958216      PMCID: PMC507711          DOI: 10.1172/JCI119072

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.

Authors:  W P Peters; E J Shpall; R B Jones; G A Olsen; R C Bast; J P Gockerman; J O Moore
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

2.  Receptor-mediated gene delivery and expression in vivo.

Authors:  G Y Wu; C H Wu
Journal:  J Biol Chem       Date:  1988-10-15       Impact factor: 5.157

3.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

4.  Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow.

Authors:  C Tondini; S A Pap; D F Hayes; A D Elias; D W Kufe
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

5.  Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli lacZ.

Authors:  G P Nolan; S Fiering; J F Nicolas; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.

Authors:  C Taswell
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.

Authors:  E L Friedman; D F Hayes; D W Kufe
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

8.  Elimination of malignant clonogenic breast cancer cells from human bone marrow.

Authors:  I C Anderson; E J Shpall; D S Leslie; K Nustad; J Ugelstad; W P Peters; R C Bast
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

9.  Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.

Authors:  D Kufe; G Inghirami; M Abe; D Hayes; H Justi-Wheeler; J Schlom
Journal:  Hybridoma       Date:  1984

10.  Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene.

Authors:  M Abe; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

View more
  11 in total

1.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Efficient c-kit receptor-targeted gene transfer to primary human CD34-selected hematopoietic stem cells.

Authors:  Q Zhong; P Oliver; W Huang; D Good; V La Russa; Z Zhang; J R Cork; R W Veith; C Theodossiou; J K Kolls; P Schwarzenberger
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Receptor-targeted recombinant adenovirus conglomerates: a novel molecular conjugate vector with improved expression characteristics.

Authors:  P Schwarzenberger; J D Hunt; E Robert; C Theodossiou; J K Kolls
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.

Authors:  Caijun Sun; Liqiang Feng; Yinfeng Zhang; Lijun Xiao; Weiqi Pan; Chufang Li; Linqi Zhang; Ling Chen
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

5.  Oncolytic virotherapy for multiple myeloma: past, present, and future.

Authors:  Chandini M Thirukkumaran; Don G Morris
Journal:  Bone Marrow Res       Date:  2011-05-10

6.  Targeting Radiotherapy to Cancer by Gene Transfer.

Authors:  R. J. Mairs; M. Boyd
Journal:  J Biomed Biotechnol       Date:  2003

Review 7.  Mucins in neoplasms of pancreas, ampulla of Vater and biliary system.

Authors:  Dimitrios Moschovis; Giorgos Bamias; Ioanna Delladetsima
Journal:  World J Gastrointest Oncol       Date:  2016-10-15

8.  A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.

Authors:  Jordan M Winter; Laura H Tang; David S Klimstra; Murray F Brennan; Jonathan R Brody; Flavio G Rocha; Xiaoyu Jia; Li-Xuan Qin; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Eileen M O'Reilly; Peter J Allen
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

9.  Transcriptional Targeting in Cancer Gene Therapy.

Authors:  Tracy Robson; David G. Hirst
Journal:  J Biomed Biotechnol       Date:  2003

Review 10.  Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.

Authors:  Nancy Y Villa; Grant McFadden
Journal:  Curr Pathobiol Rep       Date:  2018-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.